The Hippo pathway in chemotherapeutic drug resistance

International Journal of Cancer

Volumn 137, Issue 12, 2015, Pages 2667-2773

  Zhao, Yulei ^a   Yang, Xiaolong ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

chemotherapy; drug resistance; Hippo pathway; therapeutic target

Indexed keywords

ALPHA CATENIN; ANGIOMOTIN; CYCLIN A; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; MEMBRANE PROTEIN; MERLIN; ONCOPROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MST1; PROTEIN MST2; PROTEIN ZO1; PROTEIN ZO2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HIPPO PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; COLON CANCER; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE FUNCTION; HIPPO SIGNALING PATHWAY; HUMAN; LATS1 GENE; LATS2 GENE; LIVER CELL CARCINOMA; LUNG CANCER; NONHUMAN; ONCOGENE; ONCOGENE TAZ; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TARGETING; RASSF1A GENE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; DRUG RESISTANCE; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84943608896     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29293     Document Type: Review

References (105)

1. Devita VT, Chu E,. A history of cancer chemotherapy. Cancer Res 2008; 68: 8643-53
2. Chabner BA, Roberts TG, Jr,. Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5: 65-72
3. Longley DB, Johnston PG,. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-92
4. Pan D,. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491-505
5. Yu F, Guan K,. The Hippo pathway;: regulators and regulations. Genes Dev 2013; 27: 355-71
6. Chan SW, Lim CJ, Huang C, et al. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene 2011; 30: 600-10
7. Halder G, Johnson RL,. Hippo signaling: growth control and beyond. Development 2011; 138: 9-22
8. Harvey KF, Zhang X, Thomas DM,. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246-57
9. Harvey K, Tapon N,. The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network. Nat Rev Cancer 2007; 7: 182-91
10. Hiemer SE, Varelas X,. Stem cell regulation by the Hippo pathway. Biochim Biophys Acta 2013; 1830: 2323-34
11. Zhao B, Lei Q-Y, Guan K-L,. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008; 20: 638-46
12. Zhao B, Tumaneng K, Guan K-L,. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13: 877-83
13. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-61
14. Liu C-Y, Zha Z-Y, Zhou X, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem 2010; 285: 37159-69
15. Lei Q-Y, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28: 2426-36
16. Zhao B, Li L, Tumaneng K, et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010; 24: 72-85
17. Thompson BJ, Cohen SM,. The Hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in Drosophila. Cell 2006; 126: 767-74
18. Lamar JM, Stern P, Liu H, et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 2012; 109: E2441-50
19. Yang N, Morrison CD, Liu P, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 2012; 11: 2922-30
20. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006; 103: 12405-10
21. Bartucci M, Dattilo R, Moriconi C, et al., TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. Feb 17, 2014 [Epub ahead of print]
22. St John MA, Tao W, Fei X, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999; 21: 182-6
23. Zhou D, Conrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16: 425-38
24. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-33
25. Chan SW, Lim CJ, Guo K, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68: 2592-8
26. Wang X, Su L, Ou Q,. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer 2012; 48: 1227-34
27. Su LL, Ma WX, Yuan JF, et al. Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors. Chin Med J (Engl) 2012; 125: 4003-8
28. Noguchi S, Saito A, Horie M, et al. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. Clin Cancer Res 2014; 20: 4660-72
29. Han S, Bai E, Jin G, et al. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res 2014; 2014: 261365
30. Wang L, Shi S, Guo Z, et al. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One 2013; 8: e65539
31. Yuen H-F, McCrudden CM, Huang Y-H, et al. TAZ expression as a prognostic indicator in colorectal cancer. PLoS One 2013; 8: e54211
32. Takahashi Y, Miyoshi Y, Takahata C, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005; 11: 1380-5
33. Lin X-Y, Zhang X-P, Wu J-H, et al. Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. Tumour Biol 2014; 35: 6435-43
34. Sasaki H, Hikosaka Y, Kawano O, et al. Hypermethylation of the large tumor suppressor genes in Japanese lung cancer. Oncol Lett 2010; 1: 303-7
35. Chan EHY, Nousiainen M, Chalamalasetty RB, et al. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 2005; 24: 2076-86
36. Minoo P, Zlobec I, Baker K, et al. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol 2007; 20: 331-8
37. Ren A, Yan G, You B, et al. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res 2008; 68: 2266-74
38. Visser S, Yang X,. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 2010; 9: 3892-903
39. Visser S, Yang X,. Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarray. Gene 2010; 449: 22-9
40. Ji D, Deeds SL, Weinstein EJ,. A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol Rep 2007; 18: 1499-505
41. Ho K, Zhou Z, She Y, et al. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 tumor-suppressor stability. PNAS 2011; 108: 4870-5
42. Hansen TM, Rossi M, Roperch JP, et al. Itch inhibition regulates chemosensitivity in vitro. Biochem Biophys Res Commun 2007; 361: 33-6
43. Kawahara M, Hori T, Chonabayashi K, et al. Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 2008; 112: 3856-66
44. Lit LC, Scott S, Zhang H, et al. LATS2 is a modulator of estrogen receptor alpha. Anticancer Res 2013; 33: 53-63
45. Takahashi Y, Miyoshi Y, Morimoto K, et al. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. J Cancer Res Clin Oncol 2007; 133: 501-9
46. Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962-71
47. Jeong W, Kim S-B, Sohn BH, et al. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res 2014; 34: 811-7
48. Xia Y, Chang T, Wang Y, et al. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One 2014; 9: e91770
49. Zhang X, George J, Deb S, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011; 30: 2810-22
50. Huo X, Zhang Q, Liu AM, et al. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellular carcinoma. Oncol Rep 2013; 29: 840-6
51. Touil Y, Igoudjil W, Corvaisier M, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res 2014; 20: 837-46
52. Jiang N, Hjorth-Jensen K, Hekmat O, et al., In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth. Oncogene, Jul 28, 2014 [Epub ahead of print]
53. Hao Y, Chun A, Cheung K, et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283: 5496-509
54. Zhao Y, Khanal P, Savage P, et al. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway. Cancer Res 2014; 74: 4493-503
55. Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26: 1300-5
56. Oka T, Remue E, Meerschaert K, et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J 2010; 432: 461-72
57. Zhao B, Li L, Lu Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25: 51-63
58. Schlegelmilch K, Mohseni M, Kirak O, et al. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell 2011; 144: 782-95
59. Oka T, Sudol M,. Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. Genes Cells 2009; 14: 607-15
60. Huang J, Nagatomo I, Suzuki E, et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 2013; 32: 2220-9
61. Zhang J, Ji J-Y, Yu M, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 2009; 11: 1444-50
62. Mao B, Hu F, Cheng J, et al. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene 2014; 33: 1468-74
63. Zhao Y, Yang X,. WWTR1 (WW domain containing transcription regulator 1). Atlas Genet Cytogenet Oncol Haematol 2014; 18: 849-852
64. Lai D, Ho KC, Hao Y, et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011; 71: 2728-38
65. Chan SW, Lim CJ, Chong YF, et al. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286: 7018-26
66. Varelas X, Samavarchi-Tehrani P, Narimatsu M, et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. Dev Cell 2010; 19: 831-44
67. Remue E, Meerschaert K, Oka T, et al. TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner. FEBS Lett 2010; 584: 4175-80
68. Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147: 759-72
69. Menendez JA, Vellon L, Mehmi I, et al. A novel CYR61-triggered "CYR61-alphavbeta3 integrin loop" regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 2005; 24: 761-79
70. Grusche FA, Richardson HE, Harvey KF,. Upstream regulation of the hippo size control pathway. Curr Biol 2010; 20: R574-82
71. Hesson LB, Cooper WN, Latif F,. The role of RASSF1A methylation in cancer. Dis Markers 2007; 23: 73-87
72. Liu L, Tommasi S, Lee DH, et al. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003; 22: 8125-36
73. Giovinazzi S, Lindsay CR, Morozov VM, et al. Regulation of mitosis and taxane response by Daxx and Rassf1. Oncogene 2012; 31: 13-26
74. Kassler S, Donninger H, Birrer MJ, et al. RASSF1A and the Taxol response in ovarian cancer. Mol Biol Int 2012; 2012: 263267
75. Trofatter J,. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800
76. Bai Y, Liu Y-J, Wang H, et al. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 2007; 26: 836-50
77. Hamaratoglu F, Willecke M, Kango-Singh M, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006; 8: 27-36
78. Genevet A, Wehr MC, Brain R, et al. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell 2010; 18: 300-8
79. Yu J, Zheng Y, Dong J, et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell 2010; 18: 288-99
80. Baumgartner R, Poernbacher I, Buser N, et al. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev Cell 2010; 18: 309-16
81. Zhang N, Bai H, David KK, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010; 19: 27-38
82. Lau Y-KI, Murray LB, Houshmandi SS, et al. Merlin is a potent inhibitor of glioma growth. Cancer Res 2008; 68: 5733-42
83. Xu Y, Stamenkovic I, Yu Q,. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 2010; 70: 2455-64
84. Badouel C, Gardano L, Amin N, et al. The FERM-domain protein Expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie. Dev Cell 2009; 16: 411-20
85. Visser-Grieve S, Hao Y, Yang X,. Human homolog of Drosophila expanded, hEx, functions as a putative tumor suppressor in human cancer cell lines independently of the Hippo pathway. Oncogene 2011; 31: 1189-95
86. Singh A, Settleman J,. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-51
87. Abdullah LN, Chow EK-H,. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013; 2: 3
88. Steg AD, Bevis KS, Katre AA, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012; 18: 869-81
89. Song S, Ajani JA, Honjo S, et al. Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal cancer cells. Cancer Res 2014; 74: 4170-82
90. Varelas X, Miller BW, Sopko R, et al. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell 2010; 18: 579-91
91. Heallen T, Zhang M, Wang J, et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 2011; 332: 458-61
92. Barry ER, Camargo FD,. The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development. Curr Opin Cell Biol 2013; 25: 247-53
93. Hergovich A, Hemmings BA,. TAZ-mediated crosstalk between Wnt and Hippo signaling. Dev Cell 2010; 18: 508-9
94. Mauviel A, Nallet-Staub F, Varelas X,. Integrating developmental signals: a Hippo in the (path)way. Oncogene 2011; 31: 1743-56
95. Enomoto M, Igaki T,. Src controls tumorigenesis via JNK-dependent regulation of the Hippo pathway in Drosophila. EMBO Rep 2013; 14: 65-72
96. Vassilev A, Kaneko KJ, Shu H, et al. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001; 15: 1229-41
97. Herranz H, Hong X, Cohen SM,. Mutual repression by bantam miRNA and Capicua links the EGFR/MAPK and Hippo pathways in growth control. Curr Biol 2012; 22: 651-7
98. Reddy B, Irvine KD,. Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev Cell 2013; 24: 459-71
99. Fan R, Kim N-G, Gumbiner BM,. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc Natl Acad Sci USA 2013; 110: 2569-74
100. O'Neill E, Kolch W,. Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle 2005; 4: 365-7
101. Ischenko I, Camaj P, Seeliger H, et al. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene 2008; 27: 7212-22
102. Hawthorne VS, Huang W-C, Neal CL, et al. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res 2009; 7: 592-600
103. Jin W, Wu L, Liang K, et al. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 2003; 89: 185-91
104. Yu H-G, Ai Y-W, Yu L-L, et al. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 2008; 122: 433-43
105. Kim S-H, Juhnn Y-S, Song Y-S,. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 2007; 1095: 82-9